Abstract: The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a viral infection. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: The present invention relates to a method for the production of a cellular allogeneic vaccine, which is based upon an allogeneic APC, comprising the following steps: isolation of an APC from a subject or providing an APC already established and/or isolated from a myeloid leukemia cell line, and modifying the APC with an antigen using any of the following methods: pulsing, transfection, infection or fusion; treatment using an agent capable of removing sialic acid on cell surfaces; and optionally culturing the APC in a suitable medium, an allogeneic vaccine obtainable by the above method, a composition comprising said vaccine and a pharmaceutically acceptable carrier and therapeutic use of said vaccine or said composition.

Abstract: A packaging container comprises a first portion formed of a first material or material combination mainly consisting of plastic, a second portion formed of a second material or material combination mainly consisting of a fibre based packaging laminate, and a pouring opening formed in the first portion. The second portion is provided with an arrangement for separating the entire first portion from the second portion.

Abstract: This invention pertains to cancer immunotherapy, by providing a proinflammatory dendritic cell (DC), which has been stimulated to maturation ex vivo by specific treatment, a method for such treatment and a composition comprising the proinflammatory DC. The DC may be used as a cell based immunotherapy for inhibiting tumor cell proliferation.

Abstract: The disclosure relates to a method of producing a blank (50a, 50b) of thermosealable and creased packaging laminate for a microwave-friendly packaging container, comprising the steps of: (a) advancing a continuous web (1) of a base laminate (10) in a conversion line for the packaging laminate so that continuous blanks for said packaging containers are oriented with their top-to-bottom direction transversely of the machine direction of the conversion line and with a top-to-bottom interface (51), (b) providing said base laminate (10) with creases and cutting into said blanks (50a, 50b) of the packaging laminate, a continuous strip (2) of a material which conducts heat and electricity being applied in the machine direction in a region over said top-to-top/bottom interface (51) and in conjunction with step (a), and an elongate opening indication (53) being provided, before or after the application of the strip (2) so that the opening indication is positioned within the region of said strip.

Abstract: The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: A method involving the hot fill of foods in packaging containers constructed from a paperboard laminate comprises the food being filled in the packaging container with at least one component at a temperature of at least 80°, but below 100°, whereafter the packaging containers are closed and sealed and the packaging containers with their food contents are thereafter held hot during a predetermined period of time by contact with a heat holding medium at a temperature of at least 80°, but below 100°. The heat holding medium is present substantially in gas and/or vapour phase. An apparatus involving the hot fill of foods is also disclosed.

Abstract: A method involving the hot fill of foods in packaging containers constructed from a paperboard laminate comprises the food being filled in the packaging container with at least one component at a temperature of at least 80° C., but below 100° C., whereafter the packaging containers are closed and sealed and the packaging containers with their food contents are thereafter held hot during a predetermined period of time by contact with a heat holding medium at a temperature of at least 80° C., but below 100° C. The heat holding medium is present substantially in gas and/or vapour phase. An apparatus involving the hot fill of foods Information Disclosure Statement also disclosed.

Abstract: A method of packing a food, and heat treating the food for purposes of extending its shelf-life, in a packaging container made of a packaging laminate comprising a core layer of paper or paperboard and outer plastic coatings of polyethylene, preferably low density polyethylene. The filled and sealed packaging container is conveyed through a treatment chamber or tunnel comprising a heating zone in which the packaging container is heated to the desired treatment temperature, e.g. 80-100° C., a holding zone in which the packaging container is kept at the desired treatment temperature and a cooling zone, wherein the packaging container during both of these treatment phases is subjected to an outer support pressure of less than 0.5 bar, preferably 0.2-0.3 bar.

Abstract: A 3-substituted 4-(phenyl-N-alkyl)-piperazine compound of the following formula: wherein R1 is selected from the group consisting of OSO2CF3, OSO2CH3, SO2R3, COCF3, COCH3 and COCH2CH3, wherein R3 is as defined hereafter; R2 is selected from the group consisting of C1-C4 alkyls, allyl, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl and 4,4,4-trifluorobutyl; R3 is selected from the group consisting of C1-C3 alkyls, CF3, and N(CH3)2; with the proviso that when R1 is SO2R3 and R3 is a C1-C3 alkyl, then R2 is not CH2CH2OCH3; or a pharmaceutically acceptable salt thereof are provided. Also, pharmaceutical compositions comprising the above compound and methods wherein the above compound is used for the treatment of various disorders are provided.

Abstract: The disclosure relates to a method of producing a blank (50a, 50b) of thermosealable and creased packaging laminate for a microwave-friendly packaging container, comprising the steps of: (a) advancing a continuous web (1) of a base laminate (10) in a conversion line for the packaging laminate so that continuous blanks for said packaging containers are oriented with their top-to-bottom direction transversely of the machine direction of the conversion line and with a top-to-bottom interface (51), (b) providing said base laminate (10) with creases and cutting into said blanks (50a, 50b) of the packaging laminate, a continuous strip (2) of a material which conducts heat and electricity being applied in the machine direction in a region over said top-to-top/bottom interface (51) and in conjunction with step (a), and an elongate opening indication (53) being provided, before or after the application of the strip (2) so that the opening indication is positioned within the region of said strip.

Abstract: The present invention relates to a method for the production of a cellular allogeneic vaccine, which is based upon an allogeneic APC, comprising the following steps: isolation of an APC from a subject or providing an APC already established and/or isolated from a myeloid leukemia cell line, and modifying the APC with an antigen using any of the following methods: pulsing, transfection, infection or fusion; treatment using an agent capable of removing sialic acid on cell surfaces; and optionally culturing the APC in a suitable medium, an allogeneic vaccine obtainable by the above method, a composition comprising said vaccine and a pharmaceutically acceptable carrier and therapeutic use of said vaccine or said composition.

Abstract: A 3-substituted 4-(phenyl-N-alkyl)-piperazine compound of the following formula: wherein R1 is selected from the group consisting of OSO2CF3, OSO2CH3, SO2R3, COCF3, COCH3 and COCH2CH3, wherein R3 is as defined hereafter; R2 is selected from the group consisting of C1-C4 alkyls, allyl, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl and 4,4,4-trifluorobutyl; R3 is selected from the group consisting of C1-C3 alkyls, CF3, and N(CH3)2; with the proviso that when R1 is SO2R3 and R3 is a C1-C3 alkyl, then R2 is not CH2CH2OCH3; or a pharmaceutically acceptable salt thereof are provided. Also, pharmaceutical compositions comprising the above compound and methods wherein the above compound is used for the treatment of various disorders are provided.

Abstract: New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1) wherein X is N, CH, or C, however X may only be C when the compound comprises a double bind at the dotted line; R1 is CF3, OSO2CF3, OSO2CH3, SOR7, SO2R7, COR7, CN, OR3, NO2, CONHR3, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br, or I; R2 is F, Cl, Br, I, CN, CF3, CH3, OCH3, OH, and NH2; R3 and R4 are independently H or a C1-C4 alkyl; R5 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or —(CH2)R6; R6 is a C3-C6 cycloalkyl, 2-tetrahydrofurane, or 3-tetra-hydrofurane; R7 is a C1-C3 alkyl, CF3, or N(R4)2, and pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed.

Abstract: A method for the production of a cellular allogeneic vaccine, which is based upon an allogeneic APC, includes the following steps: a) isolation of an APC from a subject or providing an APC already established and/or isolated from a myeloid leukemia cell line, and b) modifying the APC with an antigen using any of the following methods: pulsing, transfection, infection or fusion; c) treatment using an agent capable of removing sialic acid on cell surfaces; and optionally d) culturing the APC in a suitable medium, an allogeneic vaccine obtainable by the above method, a composition comprising the vaccine and a pharmaceutically acceptable carrier and therapeutic use of the vaccine or the composition.

Abstract: New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R1 is OSO2CF3, OSO2CH3, SOR3, SO2R3, COR3, NO2, or CONHR3 and when X is CH or C R1 may also be CF3, CN, F, Cl, Br, or I; R2 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or —(CH2)—R4; R3 is a C1-C3 alkyl CF3, or N(R2)2; R4 is a C3-C6 cycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed.

Abstract: System and method for generating hydrogen fuel for a fuel cell. The system has a reforming process device for implementing a reforming process that converts primary fuel to hydrogen. At least one cleaning device is included that cleans a flow of hydrogen fuel leaving the reforming process. The cleaning device includes a membrane (22) having selective permeability for CO, and the membrane (22) is essentially composed of ceramic material. Preferably, the system is adapted for inclusion on a vehicle.

Abstract: New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R1 is OSO2CF3, OSO2CH3, SOR3, SO2R3, COR3, NO2, or CONHR3 and when X is CH or C R1 may also be CF3, CN, F, Cl, Br, or I; R2 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or —(CH2)—R4; R3 is a C1-C3 alkyl, CF3, or N(R2)2; R4 is a C3-C6 cycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed.

Abstract: New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1) wherein X is N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R1 is OSO2CF3, OSO2CH3, SOR5, SO2R5, COR5, CN, NO2, CONHR5, CF3, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br, or I; R2 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or —(CH2)—R6; R3 and R4 are independently selected from the group consisting of H and C1-C4 alkyls, however both R3 and R4 cannot be H at the same time; R5 is C1-C3 alkyls, CF3, or N(R2)2; R6 is a C3-C6 cycloalkyl, 2-tetrahydrofurane, or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used are disclosed.

Abstract: New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1) wherein X is N, CH, or C, however X may only be C when the compound comprises a double bind at the dotted line; R1 is CF3, OSO2CF3, OSO2CH3, SOR7, SO2R7, COR7, CN, OR3, NO2, CONHR3, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br, or I; R2 is F, Cl, Br, I, CN, CF3, CH3, OCH3, OH, and NH2; R3 and R4 are independently H or a C1-C4 alkyl; R5 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or —(CH2)R6; R6 is a C3-C6 cycloalkyl, 2-tetrahydrofurane, or 3-tetra-hydrofurane; R7 is a C1-C3 alkyl, CF3, or N(R4)2, and pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed.